Our business model is based on collaborating and partnering with potential pharmaceutical companies, biotech companies and academic research institutions to create novel and best-in-class antibodies for diagnostic and therapeutic applications within a shorter timeframe than that of traditional antibody development work. Our aim is to develop products that can help patients and improve their quality of life.
We are seeking investors with strong financial resources. Taking advantage of human hybridoma, our TOHU™ platform does not represent a progressive advance but a fundamental change towards discovering first-in-class antibodies for a board range of clinical applications. We offer investors the opportunity to take part in the commercialization of our state-of-the-art TOHU™ Platform and benefit from it.
Creative Biolabs is proud to announce a newly developed platform for production of human hybridomas for the development of monoclonal antibodies for a wide variety of human therapeutic purposes. Our TOHU™ human hybridoma is an innovation with super efficiency. It overcomes limitations of low fusion efficiency, reduced binding affinity and low yield in existing hybridoma technologies, thus offering an important tool for development of human monoclonal antibodies.
If you are interested in keeping up to date with our technology or participating in either option, please contact us!
Get in touchOur TOHU™ human hybridomas platform has been designed to develop antibodies for research purposes only. Do not use them for clinical or therapeutic applications.
